Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL).

Santomasso BD, Park JH, Salloum D, Rivière I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.

Cancer Discov. 2018 Jun 7. pii: CD-17-1319. doi: 10.1158/2159-8290.CD-17-1319. [Epub ahead of print]

PMID:
29880584
2.

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.

Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH, Brentjens RJ.

Cell Rep. 2018 May 15;23(7):2130-2141. doi: 10.1016/j.celrep.2018.04.051.

3.

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.

Smith EL, Staehr M, Masakayan R, Tatake IJ, Purdon TJ, Wang X, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Riviere I, Liu C, Brentjens RJ.

Mol Ther. 2018 Jun 6;26(6):1447-1456. doi: 10.1016/j.ymthe.2018.03.016. Epub 2018 Mar 28.

PMID:
29678657
4.

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ.

Sci Rep. 2017 Sep 5;7(1):10541. doi: 10.1038/s41598-017-10940-8.

5.

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.

Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ.

Leukemia. 2017 Aug;31(8):1788-1797. doi: 10.1038/leu.2016.373. Epub 2016 Dec 7.

6.

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ.

Oncoimmunology. 2015 Jan 23;4(3):e994446. eCollection 2015 Mar.

7.

Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.

Curran KJ, Seinstra BA, Nikhamin Y, Yeh R, Usachenko Y, van Leeuwen DG, Purdon T, Pegram HJ, Brentjens RJ.

Mol Ther. 2015 Apr;23(4):769-78. doi: 10.1038/mt.2015.4. Epub 2015 Jan 13.

8.

IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.

Pegram HJ, Purdon TJ, van Leeuwen DG, Curran KJ, Giralt SA, Barker JN, Brentjens RJ.

Leukemia. 2015 Feb;29(2):415-22. doi: 10.1038/leu.2014.215. Epub 2014 Jul 9.

9.

Loved one's body in the anatomy laboratory.

McNeill PM, Kerridge IH, Purdon T.

Anat Rec B New Anat. 2004 Mar;277(1):10-3.

10.

Career transitions:planning for alternative futures.

Purdon TF, Cefalo RC, Stenchever MA.

Obstet Gynecol. 2002 May;99(5 Pt 1):828-31.

PMID:
11978294
11.

Caring.

Purdon TF.

Obstet Gynecol. 2001 Oct;98(4):545-9. No abstract available.

PMID:
11576565
12.

AAFP/ACOG educational and practice guidelines.

Harr PB, Purdon TF.

Am Fam Physician. 1998 Jul;58(1):38-9. No abstract available.

13.

Effects of thermal endometrial ablation. Clinicopathologic correlations.

Davis JR, Maynard KK, Brainard CP, Purdon TF, Sibley MA, King DD.

Am J Clin Pathol. 1998 Jan;109(1):96-100.

PMID:
9426524
14.

Use of needle localization for difficult Norplant removal.

Lang JF, Heine MW, Purdon TF.

Am J Obstet Gynecol. 1994 Oct;171(4):1161-2. No abstract available.

PMID:
7818681
15.

Narrow Caliber Office Hysteroscope

Munro MG, Jensen J, Purdon TF.

J Am Assoc Gynecol Laparosc. 1994 Aug;1(4, Part 2):S24.

PMID:
9073726
16.

Some macro and micro aspects of economics in obstetrics and gynecology.

Purdon TF.

Obstet Gynecol Surv. 1994 Mar;49(3):153-4. No abstract available.

PMID:
8164914
17.

Pyovesiculosis as a cause of chronic vulvovaginitis. Report of 3 cases.

Burnett RG, Purdon TF.

Obstet Gynecol. 1965 Oct;26(4):508-10. No abstract available.

PMID:
5317901

Supplemental Content

Loading ...
Support Center